First-Line Treatment for Patients With CML in Chronic Phase: Second-Generation TKIs Are the Therapy of Choice

被引：0
|
作者：
Cortes, Jorge [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
ONCOLOGY-NEW YORK | 2013年 / 27卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：781 / 781
页数：1
相关论文
共 50 条
  • [41] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FIRST-LINE SECOND-GENERATION TYROSINE KINASE INHIBITORS
    Lee, S.
    Choi, S.
    Kim, S.
    Bang, J.
    Oh, Y.
    Park, J.
    Jeon, H.
    Jang, E.
    Kim, D.
    HAEMATOLOGICA, 2013, 98 : 51 - 52
  • [42] Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs
    Breccia, Massimo
    Latagliata, Roberto
    Stagno, Fabio
    Gozzini, Antonella
    Abruzzese, Elisabetta
    Rossi, Antonella Russo
    Santopietro, Michelina
    Cannella, Laura
    Sora, Federica
    Vigneri, Paolo
    Trawinska, Malgorzata
    Sica, Simona
    Specchia, Giorgina
    Santini, Valeria
    Alimena, Giuliana
    BLOOD, 2010, 116 (21) : 1395 - 1396
  • [43] Is exercise therapy the first-line treatment for chronic pain?
    Senba, Emiko
    NEUROBIOLOGY OF PAIN, 2024, 15
  • [44] First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia
    Balsat, Marie
    Alcazer, Vincent
    Etienne, Gabriel
    Huguet, Francoise
    Berger, Marc
    Cayssials, Emilie
    Charbonnier, Aude
    Escoffre-Barbe, Martine
    Johnson-Ansah, Hyacinthe
    Legros, Laurence
    Roy, Lydia
    Delmer, Alain
    Ianotto, Jean-Christophe
    Orvain, Corentin
    Larosa, Fabrice
    Meunier, Mathieu
    Ame, Shanti
    Andreoli, Annalisa
    Cony-Makhoul, Pascale
    Morisset, Stephane
    Tigaud, Isabelle
    Rea, Delphine
    Nicolini, Franck Emmanuel
    LEUKEMIA RESEARCH, 2023, 130
  • [45] First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI
    Saglio, Giuseppe
    Jabbour, Elias
    LEUKEMIA & LYMPHOMA, 2018, 59 (07) : 1523 - 1538
  • [46] Dasatinib as first-line therapy for CML-CP
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2014, 15 (01): : E7 - E7
  • [47] First-line therapy for CML: nilotinib comes of age
    Davies, Jeff
    LANCET ONCOLOGY, 2011, 12 (09): : 826 - 827
  • [48] Retrospective real-world comparison of clinical and economic burden between first-generation and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).
    Smith, T. Alexander
    Verma, Sumit
    Liu, Yi
    Sikirica, Slaven
    Janjan, Nora Anita
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study
    Jain, Preetesh
    Kantarjian, Hagop
    Jabbour, Elias
    Gonzalez, Graciela Nogueras
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Gachimova, Evguenia
    Ferrajoli, Alessandra
    Kornblau, Steven
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge
    LANCET HAEMATOLOGY, 2015, 2 (09): : E376 - E383
  • [50] Lymphocytosis Following First-Line Treatment for CML In Chronic Phase With Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib
    Schiffer, Charles A.
    Cortes, Jorge E.
    Saglio, Giuseppe
    le Coutre, Philipp
    Guilhot, Francois
    Bahceci, Erkut
    Dejardin, David
    Shah, Neil P.
    BLOOD, 2010, 116 (21) : 161 - 162
12345